
Browsing restrictions can be lifted for a fee.
Chi Sheng Pharma & Biotech Co., Ltd engages in the manufacturing, processing, sale, and import and export trade of pharmaceuticals, medical products, cosmetics, health foods, and medical equipment in Taiwan and internationally. Its products portfolio includes antibiotics and chemotherapeutic agents; plasma substitutes and amino acid preparations; water nutrients and electrolyte preparations; vitamins; hepatotropic agents; hormones and adrenal cortical steroids; autonomic nerves agents; antihistamines and antipruritics; antipyretics and analgesics; antitussives and anti-asthmas; gastro-intestinal preparations; local anesthetic preparations; hemodialysis concentrate and external solutions; peritoneal dialysis solutions; and others. The company also offers medical devices, fat emulsion products, anesthetic products, hemostatics solutions, food products, functional drinks, skin care products, and veterinary medicinal products. In addition, it offers externally applied medicines, including contact lens, salt, and iodine solutions. Chi Sheng Pharma & Biotech Co., Ltd was founded in 1962 and is headquartered in Hsinchu, Taiwan.
4111
濟生
-0.67%
(-0.01)
The most recent financial report for 濟生 (4111) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 4111's short-term business performance and financial health. For the latest updates on 4111's earnings releases, visit this page regularly.
According to historical valuation range analysis, 濟生 (4111)'s current price-to-earnings (P/E) ratio is 8.72, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
According to the latest financial report, 濟生 (4111) reported an Operating Profit of 42.93M with an Operating Margin of 12.55% this period, representing a growth of 68.97% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, 濟生 (4111) announced revenue of 342.14M, with a Year-Over-Year growth rate of 20.36%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
At the end of the period, 濟生 (4111) held Total Cash and Cash Equivalents of 421.85M, accounting for 0.22 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, 濟生 (4111) achieved the “three margins increasing” benchmark, with a gross margin of 38.69%%, operating margin of 12.55%%, and net margin of 13.19%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 4111's profit trajectory and future growth potential.
According to the past four quarterly reports, 濟生 (4111)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.75. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
濟生 (4111)'s Free Cash Flow (FCF) for the period is 2.11M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 125.01% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.